MX2011013781A - Anticuerpos anti-vegf y sus usos. - Google Patents

Anticuerpos anti-vegf y sus usos.

Info

Publication number
MX2011013781A
MX2011013781A MX2011013781A MX2011013781A MX2011013781A MX 2011013781 A MX2011013781 A MX 2011013781A MX 2011013781 A MX2011013781 A MX 2011013781A MX 2011013781 A MX2011013781 A MX 2011013781A MX 2011013781 A MX2011013781 A MX 2011013781A
Authority
MX
Mexico
Prior art keywords
vegf antibodies
vegf
antibodies
overproduction
activity
Prior art date
Application number
MX2011013781A
Other languages
English (en)
Spanish (es)
Inventor
David B Powers
Robert B Dubridge
Fiona Harding
Yoshiko Akamatsu
Original Assignee
Abbott Biotherapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42543312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011013781(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Biotherapeutics Corp filed Critical Abbott Biotherapeutics Corp
Publication of MX2011013781A publication Critical patent/MX2011013781A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
MX2011013781A 2009-06-17 2010-06-17 Anticuerpos anti-vegf y sus usos. MX2011013781A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21800509P 2009-06-17 2009-06-17
PCT/US2010/039029 WO2010148223A2 (en) 2009-06-17 2010-06-17 Anti-vegf antibodies and their uses

Publications (1)

Publication Number Publication Date
MX2011013781A true MX2011013781A (es) 2012-05-29

Family

ID=42543312

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2011013781A MX2011013781A (es) 2009-06-17 2010-06-17 Anticuerpos anti-vegf y sus usos.
MX2014001638A MX346002B (es) 2009-06-17 2010-06-17 Anticuerpos anti-vegf y sus usos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014001638A MX346002B (es) 2009-06-17 2010-06-17 Anticuerpos anti-vegf y sus usos.

Country Status (26)

Country Link
US (1) US9079953B2 (cg-RX-API-DMAC10.html)
EP (2) EP2443150B1 (cg-RX-API-DMAC10.html)
JP (1) JP5785941B2 (cg-RX-API-DMAC10.html)
KR (1) KR20120034739A (cg-RX-API-DMAC10.html)
CN (1) CN102482349B (cg-RX-API-DMAC10.html)
AU (1) AU2010262836B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI1012321A8 (cg-RX-API-DMAC10.html)
CA (1) CA2765755C (cg-RX-API-DMAC10.html)
CL (1) CL2011003182A1 (cg-RX-API-DMAC10.html)
CO (1) CO6480962A2 (cg-RX-API-DMAC10.html)
CR (1) CR20110653A (cg-RX-API-DMAC10.html)
EC (1) ECSP12011584A (cg-RX-API-DMAC10.html)
ES (2) ES2534355T3 (cg-RX-API-DMAC10.html)
GT (1) GT201100326A (cg-RX-API-DMAC10.html)
HK (1) HK1211961A1 (cg-RX-API-DMAC10.html)
IL (2) IL216835A0 (cg-RX-API-DMAC10.html)
MX (2) MX2011013781A (cg-RX-API-DMAC10.html)
NZ (1) NZ596837A (cg-RX-API-DMAC10.html)
PE (1) PE20120622A1 (cg-RX-API-DMAC10.html)
PH (1) PH12011502602A1 (cg-RX-API-DMAC10.html)
RU (1) RU2567639C2 (cg-RX-API-DMAC10.html)
SG (2) SG10201403327WA (cg-RX-API-DMAC10.html)
TW (1) TWI510248B (cg-RX-API-DMAC10.html)
UA (1) UA104626C2 (cg-RX-API-DMAC10.html)
WO (1) WO2010148223A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201109098B (cg-RX-API-DMAC10.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
JP2014505698A (ja) * 2011-02-02 2014-03-06 グラクソ グループ リミテッド 新規抗原結合タンパク質
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
WO2012140676A2 (en) 2011-04-12 2012-10-18 Appaiah C B Chimeric antibacterial polypeptides
SI3495387T1 (sl) 2012-07-13 2021-12-31 Roche Glycart Ag Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
SG11201502076SA (en) 2012-09-19 2015-04-29 Genentech Inc Methods and compositions for preventing norleucine misincorporation into proteins
WO2014052713A2 (en) 2012-09-27 2014-04-03 Massachusetts Institute Of Technology Her2-and vegf-a-binding proteins with enhanced stability
KR101279895B1 (ko) * 2012-10-24 2013-06-28 주식회사 진흥기공 유체 이송용 덕트에 결합 사용되는 댐퍼의 이중 브레이드 밀폐 장치
US20140154255A1 (en) * 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
WO2014100740A1 (en) 2012-12-21 2014-06-26 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9914770B2 (en) * 2013-04-30 2018-03-13 Intas Pharmaceuticals Ltd Cloning, expression and purification method for the preparation of ranibizumab
SI4374873T1 (sl) * 2013-07-12 2026-01-30 Astellas Us Llc Sredstvo za uporabo pri zdravljenju ali preprečevanju oftalmoloških stanj
ES2819217T3 (es) 2013-09-08 2021-04-15 Kodiak Sciences Inc Conjugados de polímeros iónicos dipolares y factor VIII
WO2015164723A1 (en) * 2014-04-25 2015-10-29 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
EP3929302A1 (en) * 2014-07-14 2021-12-29 Chugai Seiyaku Kabushiki Kaisha Method for identifying epitope on protein
EP3207128B1 (en) 2014-10-17 2022-07-27 Kodiak Sciences Inc. Butyrylcholinesterase zwitterionic polymer conjugates
CN108148135B (zh) * 2015-01-06 2020-06-12 珠海亿胜生物制药有限公司 抗vegf抗体
IL290457B2 (en) * 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
IL262207B2 (en) 2016-04-15 2026-01-01 Univ Pennsylvania Preparations for the treatment of wet age-related macular degeneration
JP2019515027A (ja) * 2016-04-15 2019-06-06 レジェンクスバイオ インコーポレーテッド 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療
CN106039309B (zh) * 2016-06-30 2024-04-19 中国人民解放军总医院第一附属医院 用于治疗恶性肿瘤造成的胸腔积液的药物组合物及其应用
RU2656160C2 (ru) 2016-08-17 2018-05-31 Закрытое Акционерное Общество "Биокад" Антитело или его антигенсвязывающий фрагмент, способный связываться с рецептором интерлейкина-6 человека
CA3076905A1 (en) * 2017-09-27 2019-04-04 The Johns Hopkins University Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab
CA3086045A1 (en) * 2017-12-19 2019-06-27 Akouos, Inc. Aav-mediated delivery of therapeutic antibodies to the inner ear
CN111699004A (zh) 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
US12558434B2 (en) 2018-02-20 2026-02-24 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CN109053895B (zh) 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
JP2022512657A (ja) * 2018-10-12 2022-02-07 トリカン・バイオテクノロジー・カンパニー・リミテッド 二機能性融合タンパク質およびその使用
CN111423512B (zh) * 2019-01-10 2024-01-05 北京比洋生物技术有限公司 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN111363038A (zh) * 2020-03-26 2020-07-03 北京纽安博生物技术有限公司 抗VEGF单域抗体及其人源化、单域抗体和IgG1-Fc构建的融合蛋白和应用
CN111808191A (zh) * 2020-05-11 2020-10-23 廊坊天光生物技术有限公司 一种用于检测血清中vegf含量的抗体对及其用途
WO2022045865A1 (ko) * 2020-08-31 2022-03-03 (주)메디톡스 항-ｖｅｇｆ 육량체 항체, 및 이를 포함하는 조성물
CA3195019A1 (en) 2020-10-06 2022-04-14 Maria Fardis Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
WO2022183418A1 (zh) * 2021-03-04 2022-09-09 百奥泰生物制药股份有限公司 抗vegf抗体制剂
AR128422A1 (es) 2022-02-02 2024-05-08 Akouos Inc Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vestibular
KR20260116273A (ko) 2024-09-20 2026-07-28 파라곤 테라퓨틱스, 인크. Pd-1 결합 단백질, vegf 및 pd-1 이중특이적 결합 단백질, 조성물 및 사용 방법
CN120248142B (zh) * 2025-06-06 2025-09-12 上海兴瑞一达生物科技有限公司 一种共表达cd47和il-15的双靶点嵌合抗原受体、car-t细胞及其应用

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
CN104231078A (zh) * 1997-04-07 2014-12-24 基因技术股份有限公司 抗-血管内皮生长因子的抗体
US20070059302A1 (en) * 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU1728800A (en) * 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
SI1135498T1 (sl) 1998-11-18 2008-06-30 Genentech Inc Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
EP1579871A1 (en) * 1998-12-22 2005-09-28 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
US6979559B2 (en) * 2000-10-12 2005-12-27 Marical, Inc. Polyvalent cation-sensing receptor in atlantic salmon
BR0116680A (pt) 2000-12-14 2005-04-05 Genentech Inc Linhagem de e. coli e método de produção de um polipeptìdeo
US6979556B2 (en) * 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
EP1356052B1 (en) 2000-12-14 2008-08-20 Genentech, Inc. Production of full antibodies in procaryotic cells
CA2369893A1 (en) 2001-02-12 2002-08-12 Warner-Lambert Company Vegf responsive cell-based assay for determining vegf bioactivity
US20040010376A1 (en) * 2001-04-17 2004-01-15 Peizhi Luo Generation and selection of protein library in silico
US20030022240A1 (en) * 2001-04-17 2003-01-30 Peizhi Luo Generation and affinity maturation of antibody library in silico
US7117096B2 (en) * 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
MXPA04007583A (es) * 2002-02-11 2005-04-25 Genentech Inc Variantes de anticuerpo con tasas mas rapidas de asociacion a antigeno.
CA2485732A1 (en) * 2002-05-20 2003-12-04 Abmaxis, Inc. Generation and selection of protein library in silico
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
MXPA05004677A (es) 2002-10-31 2005-11-17 Genentech Inc Metodos y composiciones para aumentar la produccion de anticuerpos.
WO2004065417A2 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
RS20150135A1 (sr) * 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
JP4599355B2 (ja) 2003-07-28 2010-12-15 ジェネンテック， インコーポレイテッド プロテインａアフィニティークロマトグラフィーの間のプロテインａの浸出の低減
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
US20070059336A1 (en) 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
CA2577133A1 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
WO2006043972A1 (en) 2004-10-12 2006-04-27 Amprotein Corporation Chimeric protein
MX2007004374A (es) * 2004-10-12 2008-01-29 Amprotein Corp Proteina quimerica.
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US20080207467A1 (en) * 2005-03-03 2008-08-28 Xencor, Inc. Methods for the design of libraries of protein variants
US8716195B2 (en) * 2005-11-14 2014-05-06 Bioren, Inc. Antibody ultrahumanization by predicted mature CDR blasting and cohort library generation and screening
WO2007059336A1 (en) 2005-11-18 2007-05-24 Nextrom Oy Method and apparatus for manufacturing water-free optical fiber preforms
WO2007062037A2 (en) * 2005-11-21 2007-05-31 Laboratoires Serono Sa Compositions and methods of producing hybrid antigen binding molecules and uses thereof
CN101415415A (zh) * 2006-01-23 2009-04-22 约瑟夫·P·埃里科 定向药物开发的方法和组合物
ES2603399T3 (es) * 2006-07-10 2017-02-27 Esbatech, An Alcon Biomedical Research Unit Llc Anticuerpos scFv que atraviesan capas epiteliales y/o endoteliales
US11078262B2 (en) * 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
EP2586788B1 (en) * 2007-07-09 2017-11-29 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
WO2009129538A2 (en) * 2008-04-18 2009-10-22 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions

Also Published As

Publication number Publication date
KR20120034739A (ko) 2012-04-12
IL239604A0 (en) 2015-08-31
ECSP12011584A (es) 2012-08-31
SG10201403327WA (en) 2014-10-30
EP2443150B1 (en) 2015-01-21
HK1211961A1 (en) 2016-06-03
EP2894167A1 (en) 2015-07-15
WO2010148223A2 (en) 2010-12-23
TWI510248B (zh) 2015-12-01
WO2010148223A3 (en) 2011-03-03
RU2567639C2 (ru) 2015-11-10
SG177265A1 (en) 2012-02-28
MX346002B (es) 2017-03-01
JP5785941B2 (ja) 2015-09-30
CO6480962A2 (es) 2012-07-16
US20100322931A1 (en) 2010-12-23
NZ596837A (en) 2014-02-28
CN102482349A (zh) 2012-05-30
GT201100326A (es) 2013-01-24
ZA201109098B (en) 2012-08-29
BRPI1012321A2 (pt) 2016-03-15
TW201103561A (en) 2011-02-01
UA104626C2 (ru) 2014-02-25
EP2894167B1 (en) 2017-11-08
IL216835A0 (en) 2012-02-29
IL239604A (en) 2016-08-31
CR20110653A (es) 2012-05-08
AU2010262836B2 (en) 2015-05-28
PH12011502602A1 (en) 2012-11-12
US9079953B2 (en) 2015-07-14
CL2011003182A1 (es) 2012-07-20
ES2534355T3 (es) 2015-04-21
RU2011150916A (ru) 2013-07-27
CA2765755A1 (en) 2010-12-23
JP2012530496A (ja) 2012-12-06
EP2443150A2 (en) 2012-04-25
ES2656446T3 (es) 2018-02-27
PE20120622A1 (es) 2012-05-26
CN102482349B (zh) 2017-08-25
BRPI1012321A8 (pt) 2016-09-27
CA2765755C (en) 2018-01-02
AU2010262836A1 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
ECSP12011584A (es) Anticuerpos anti-vegf y sus usos
BR112015012538A2 (pt) anticorpos anti-vegf e seus usos
ECSP11011450A (es) ANTICUERPOS ANTI-TNF-a Y SUS USOS
CO6630087A2 (es) Anticuerpos bivalentes biespecificos anti-vegf/anti-ang-2
MX353706B (es) Anticuerpos contra csf-1r humano y usos de los mismos.
GT201200058A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CO6930356A2 (es) Compuestos inhibidores de metaloenzimas
CR20140141A (es) Proteinas de funcion dual para el tratamiento de desordenes metabolicos
CR20160222U (es) Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
MX2018012394A (es) Variantes de polipeptido ph20, formulaciones y usos de las mismas.
DOP2011000333A (es) Inmunoglobulina con dominio variable dual y usos de la mismas
CR20140200A (es) Formas solidas de 3-(5-amino-2-metil-4-oxo-ah-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos
GT201400033A (es) Pirimidinas anilladas sustituidas y uso de las mismas
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
TN2012000040A1 (en) High affinity human antibodies to human angiopoietin -2
EA201201016A1 (ru) Антидоты антикоагулянтов
PH12013501971B1 (en) Anti-sclerostin antibody crystals and formulations thereof
SG178886A1 (en) Humanized anti-cdcp1 antibodies
GT201100300A (es) Piperidinas sustituidas
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3
EP2427556A4 (en) INCREASED PROTEIN PRODUCTION BY INCREASING EXPRESSION OR BZW. EFFECT OF ABC50
MX2010000823A (es) Metodo para eliminar enfermedades de plantas.
TH148737A (th) สารยับยั้งสเต็มเซลล์แฟคเตอร์
BR112015006829A2 (pt) anticorpos monoclonais para o crescimento e diferenciação do fator 15 (gdf-15)
UA103141C2 (ru) Применение анти-hsp60 антител в качестве маркеров иммунной безопасности проведения гемотрансфузий в кардиохирургии врожденных пороков сердца

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: MICROSOFT TECHNOLOGY LICENSING, LLC

FG Grant or registration